Higher-dose aflibercept for wet AMD or diabetic macular edema
Treatments studied
This study tests a higher dose of the medicine aflibercept (brand name Eylea) in people who have already had at least three eye injections for wet age-related macular degeneration or diabetic macular edema. The goal is to see how well this stronger dose works in real-life conditions and how long its effects last.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 50 years old (for wet AMD) or at least 18 (for diabetic macular edema).
- You must have been diagnosed with either neovascular (wet) age-related macular degeneration or diabetic macular edema in the eye being treated.
- You must have already received at least three eye injections of an anti-VEGF medicine (like Eylea, Lucentis, or Avastin) for that condition.
- Your doctor has already decided to start you on the higher-dose aflibercept as part of your normal care, before you joined this study.
- You cannot have certain other eye conditions or infections that could interfere with the study, and you must not have had certain steroid eye treatments recently.
- If you have diabetic macular edema, you cannot have had laser treatment in the eye within the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This trial tests a higher dose of aflibercept (8 mg) for people whose diabetic macular edema, retinal vein occlusion, or myopic choroidal neovascularization has not improved with standard treatment. The goal is to see if this stronger dose can reduce fluid and improve vision.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
Hear when a new nAMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.